

RECEIVED

3737

APR 29 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below:

SECOND SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 3737  
Patent Application  
Docket No. UF-265CXC1  
Serial No. 10/075,490

April 14, 2003

Frank C. Eisenschenk, Ph.D., Patent Attorney

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Unknown  
Art Unit : 3737  
Applicant : Julie A. Johnson  
Serial No. : 10/075,490  
Filed : February 12, 2002  
Conf. No. : 8778  
For : Beta-Adrenoceptor Genetic Polymorphisms and Obesity

RECEIVED  
MAY 28 2003  
TECH CENTER 1600/2333

Assistant Commissioner for Patents  
Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that each item of information contained in this Second Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

PCT application WO 01/11039 cited as F1 on the attached PTO/SB/08B is written in a foreign language. In accordance with MPEP §609A(3), Applicant is submitting herewith a copy of the International Search Report from International Application No. PCT/US02/04332 which was filed on February 12, 2002.

RECEIVED

APR 29 2003


Docket No. UF-265CXC1  
Serial No. 10/075,490

TECHNOLOGY CENTER R3700

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/dkt

Attachments: Form PTO/SB/08 (2 pages)  
Copy of International Search Report  
References listed thereon (3)



RECEIVED

APR 29 2003

TECHNOLOGY CENTER R37C0

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/075,490
Filing Date	February 12, 2002
First Named Inventor	Julie A. Johnson
Art Unit	3737
Examiner Name	Unknown
Attorney Docket Number	UF-265CXC1

Sheet 1 of 2

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

RECEIVED  
MAY 28 2003  
TECH CENTER 1005/2000

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	WO 01/11039 A2	02/15/2001	MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN		
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

APR 29 2003


TECHNOLOGY CENTER R3700

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

## Complete if Known

Application Number	10/075,490
Filing Date	February 12, 2002
First Named Inventor	Julie A. Johnson
Group Art Unit	3737
Examiner Name	Unknown
Attorney Docket Number	UF-265CXC1

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BÖRJESSON, M., <i>et al.</i> , "A novel polymorphism in the gene coding for the beta <sub>1</sub> -adrenergic receptor associated with the survival in patients with heart failure", <i>Euro. Heart J.</i> (2000), 21:1853-1858; The European Society of Cardiology.	
	R2	MASON, D., <i>et al.</i> , "A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human $\beta_1$ -Adrenergic Receptor" <i>J. Biol. Chem.</i> (1999), 274(18):12670-12674; The American Society for Biochemistry and Molecular Biology, Inc.	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

RECEIVED  
MAY 28 2003  
TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.